U.S. Officials Plead for More Use of Languishing Antibody Drugs

U.S. health officials are pleading for more use of Covid-19 antibody therapies from Eli Lilly and Co. and Regeneron Pharmaceuticals Inc. that have been plagued by logistical issues, lack of efficacy data and insufficient reimbursement.

The antibody treatments, touted by President Donald Trump and once feared to be subject to rationing because of demand, have instead been underused. As little as 5% of the supply available was being used in some areas in December, and utilization is now about 20% to 25% of regimens distributed to states, according to a Health and Human Services Department spokesperson.

The U.S. has more ...